TABFH2

TABFH2 is an experimental **peptide seeding inhibitor** designed to block amyloid formation in transthyretin-mediated (ATTR) amyloidosis, particularly ATTR-cardiomyopathy (ATTR-CM). As a structure-based peptide, TABFH2 binds the F and H β-strands of the amyloidogenic segment of transthyretin (TTR). By capping the terminals of TTR fibrils, it prevents the seeding process that leads to amyloid aggregation. In vitro, TABFH2 demonstrates a dose-dependent ability to completely halt amyloid formation seeded by both wild-type and mutant TTR fibrils, regardless of tissue type, resulting in a reduction in amyloid conversion. In *Drosophila* models of ATTR, TABFH2 decreased TTR amyloid deposition and improved motor function. TABFH2’s approach is complementary to TTR stabilizers, acting at a different pathological stage by targeting preformed fibril seeds. It is still in preclinical development and not approved for clinical use.[1][3][5][7]